TScan Therapeutics (NASDAQ:TCRX) Receives “Outperform” Rating from Wedbush

Wedbush reiterated their outperform rating on shares of TScan Therapeutics (NASDAQ:TCRX) in a research report report published on Tuesday,RTT News reports. They currently have a $7.00 price target on the stock. Wedbush also issued estimates for TScan Therapeutics’ Q1 2026 earnings at ($0.23) EPS, Q2 2026 earnings at ($0.24) EPS, Q3 2026 earnings at ($0.25) EPS and Q4 2026 earnings at ($0.22) EPS.

Several other equities research analysts also recently weighed in on TCRX. HC Wainwright reissued a “buy” rating and issued a $15.00 price target on shares of TScan Therapeutics in a report on Thursday, March 6th. Needham & Company LLC reissued a “buy” rating and set a $9.00 target price on shares of TScan Therapeutics in a research report on Tuesday, April 8th. Barclays decreased their price target on shares of TScan Therapeutics from $14.00 to $3.00 and set an “overweight” rating for the company in a report on Friday, March 7th. Finally, Morgan Stanley reissued an “overweight” rating and set a $10.00 price objective on shares of TScan Therapeutics in a report on Friday, March 14th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $8.50.

TScan Therapeutics Stock Up 1.1 %

NASDAQ:TCRX opened at $1.38 on Tuesday. The company’s 50-day simple moving average is $1.51 and its 200-day simple moving average is $2.75. The company has a debt-to-equity ratio of 0.13, a quick ratio of 9.56 and a current ratio of 9.56. TScan Therapeutics has a fifty-two week low of $1.02 and a fifty-two week high of $9.69. The stock has a market capitalization of $77.81 million, a P/E ratio of -1.30 and a beta of 1.06.

TScan Therapeutics (NASDAQ:TCRX) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.02. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. The business had revenue of $2.17 million for the quarter, compared to analyst estimates of $1.62 million. On average, equities analysts anticipate that TScan Therapeutics will post -1.12 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TCRX. Barclays PLC grew its position in TScan Therapeutics by 341.1% during the 3rd quarter. Barclays PLC now owns 58,067 shares of the company’s stock worth $289,000 after purchasing an additional 44,903 shares during the period. JPMorgan Chase & Co. grew its holdings in TScan Therapeutics by 94.4% during the third quarter. JPMorgan Chase & Co. now owns 31,805 shares of the company’s stock worth $158,000 after acquiring an additional 15,441 shares during the period. SG Americas Securities LLC raised its position in TScan Therapeutics by 31.2% during the fourth quarter. SG Americas Securities LLC now owns 20,415 shares of the company’s stock valued at $62,000 after acquiring an additional 4,852 shares in the last quarter. Heck Capital Advisors LLC acquired a new position in TScan Therapeutics in the fourth quarter valued at approximately $61,000. Finally, China Universal Asset Management Co. Ltd. purchased a new stake in TScan Therapeutics in the 4th quarter worth approximately $32,000. 82.83% of the stock is currently owned by institutional investors and hedge funds.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.